Dual TNFR1 antagonists and TNER2 agonists for use in renal diseases
US12083097B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 12, 2021 |
| Grant date | Sep 10, 2024 |
| Priority date | — |
| Expiry date | Nov 12, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P13/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to certain 2,4-diphenyl-1,3-dioxanes that are capable of reducing Tumor necrosis factor receptor 1 (sTNFR1) and capable of increasing Tumor necrosis factor receptor 2 (sTNFR2) and their use in the treatment of specific subpopulations with a renal disease such as diabetic nephropathy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.